Clinical Trial Update: A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial of the oral BTK inhibitor LOXO-305 (pirtobrutinib) in patients with previously treated chronic lymphocytic leukemia/small l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• LOXO-305 (pirtobrutinib)

Snippet

Sponsor: Loxo Oncology, Inc. | Conditions: Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia | Phase 1, Phase 2 | Status: COMPLETED